News

MAPLIGHT THERAPEUTICS APPOINTS ERIN PENNOCK FOFF, M.D., Ph.D., AS CHIEF MEDICAL OFFICER

MAPLIGHT THERAPEUTICS APPOINTS ERIN PENNOCK FOFF, M.D., Ph.D., AS CHIEF MEDICAL OFFICER Dr. Foff Joins MapLight to Help Further Advance the Company’s Portfolio of Novel Therapeutics for Patients with Disorders of the Central Nervous System (CNS) SAN FRANCISCO, May 11, 2021 – MapLight Therapeutics today announced it has named Erin Pennock Foff, M.D., Ph.D., as … Continued

MAPLIGHT THERAPEUTICS RECEIVES $8.1 MILLION FOR PARKINSON’S DISEASE RESEARCH

SAN FRANCISCO, CA, November 30, 2020 – MapLight Therapeutics today announced a $8.1 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to undertake a large-scale, systematic investigation of the brain circuits and mechanisms that are responsible for triggering psychiatric symptoms in Parkinson’s disease. Results will inform identification of novel drug targets … Continued

MAPLIGHT THERAPEUTICS ANNOUNCES COMPLETION OF DOSING IN PHASE 1 STUDY OF THERAPY FOR SOCIAL DEFICIT IN AUTISM SPECTRUM DISORDER

Interim data from Phase 1 clinical trial with repeated dosing in healthy volunteers demonstrates positive safety and tolerability profile for ML-004 SAN FRANCISCO, November 23, 2020 – MapLight Therapeutics today announced it has completed dosing of healthy volunteers across five cohorts in a Phase 1 clinical trial evaluating the safety of ML-004, a selective serotonin … Continued

Michael J. Fox Foundation Announces Grant Funding to MapLight Therapeutics

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces 19 new grant awards totaling more than $16.5 million to projects that serve our mission to find a cure for Parkinson’s and improved treatments for those living with the disease today. MJFF is funding as many projects as possible, collaborating with the Parkinson’s research community … Continued